Table 3.

Incidences of non-hematological side effects

	Age groups, years				Overall p value
	< 60	60–64	> 64	Total
Fatigue grade 3+4*
Treatment, % (n)
TAC	11.6 (175)	12.7 (34)	17.1 (29)	12.2 (238)	0.113
Canadian FE120C	–	–	–	–	–
A(E)C-[T/P]	8.5 (28)	11.8 (8)	16.0 (8)	44 (9.8)	0.208
ddAT	24.7 (81)	39.5 (32)	35.0 (14)	28.3 (127)	0.018
ddE-ddP	–	–	–	–	–
Stomatitis grade 3+4*
Treatment, % (n)
TAC	3.6 (54)	3.7 (10)	5.9 (10)	3.8 (74)	0.328
Canadian FE120C	6.8 (24)	9.3 (10)	14.5 (12)	8.4 (46)	0.073
A(E)C-[T/P]	1.2 (12)	0.4 (1)	2.4 (4)	1.2 (17)	0.203
ddAT	2.8 (9)	7.4 (6)	5.0 (2)	3.8 (17)	0.133
ddE-ddP	2.1 (6)	13.2 (7)	11.9 (5)	4.8 (18)	< 0.001
Diarrhea grade 3+4*
Treatment, % (n)
TAC	3.5 (53)	3.4 (9)	8.2 (14)	3.9 (76)	0.010
Canadian FE120C	1.4 (5)	3.7 (4)	2.4 (2)	2.0 (11)	0.321
A(E)C-[T/P]	0.4 (4)	0.0 (0)	0.0 (0)	0.3 (4)	0.446
ddAT	8.3 (27)	7.4 (6)	2.5 (1)	7.6 (34)	0.430
ddE-ddP	0.7 (2)	0.0 (0)	0.0 (0)	0.5 (2)	0.711
Sensory neuropathy grade 3+4*
Treatment, % (n)
TAC	1.1 (17)	2.2 (6)	1.8 (3)	1.3 (26)	0.303
Canadian FE120C	0.6 (2)	0.0 (0)	0.0 (0)	0.4 (2)	0.581
A(E)C-[T/P]	0.1 (1)	0.0 (0)	0.0 (0)	0.1 (1)	0.817
ddAT	0.9 (3)	2.5 (2)	0.0 (0)	1.1 (5)	0.384
ddE-ddP	0.0 (0)	0.0 (0)	0.0 (0)	0.0 (0)	–
Increase of liver enzymes grade 3+4
Treatment, % (n)
TAC	2.3 (34)	2.3 (5)	2.0 (3)	2.2 (42)	0.981
Canadian FE120C	2.1 (7)	1.9 (2)	2.5 (2)	2.1 (11)	0.960
A(E)C-[T/P]	2.1 (20)	2.3 (5)	0.0 (0)	1.9 (25)	0.183
ddAT	1.8 (6)	5.0 (4)	7.5 (3)	2.9 (13)	0.064
ddE-ddP	10.3 (28)	3.8 (2)	0.0 (0)	8.3 (30)	0.050
Increase of creatinine grade 3+4*
Treatment, % (n)
TAC	4.5 (68)	9.3 (25)	9.5 (16)	5.6 (109)	< 0.001
Canadian FE120C	–	–	–	–	–
A(E)C-[T/P]	0.5 (3)	2.4 (3)	1.2 (1)	0.9 (7)	0.124
ddAT	1.2 (4)	1.3 (1)	2.5 (1)	1.4 (6)	0.804
ddE-ddP	0.0 (0)	3.7 (2)	8.6 (3)	1.4 (5)	< 0.001

F = 5-fluouracil

A: adriamycin

E = epirubicin

C = cyclophosphamide

T = docetaxel

P = paclitaxel

dd = dose dense.

^*According to the National Cancer Institute Common Terminology Criteria (Version 3 Terminology).